Tissue plasminogen activator coating on implant surfaces reduces Staphylococcus aureus biofilm formation

Applied and Environmental Microbiology

Volumn 82, Issue 1, 2016, Pages 394-401

  Kwiecinski, Jakub ^a   Na, Manli ^a   Jarneborn, Anders ^a   Jacobsson, Gunnar ^c   Peetermans, Marijke ^b   Verhamme, Peter ^b   Jin, Tao ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c SKARABORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIA; BIOMEDICAL EQUIPMENT; COATINGS; MAMMALS; STERILIZERS; TISSUE;

ANTIBIOTIC RESISTANCE; BACTERIAL BIOFILM; BIOFILM FORMATION; BIOFILM INFECTIONS; BIOMASS ACCUMULATION; STAPHYLOCOCCUS AUREUS; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR (TPA);

BIOFILMS;

ANTIBIOTICS; ASSAY; BACTERIUM; BIOFILM; EXPERIMENTAL STUDY; RODENT;

BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS AUREUS;

CLOXACILLIN; FIBRIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; BIOFILM; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IN VITRO STUDY; METABOLISM; MOUSE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTY;

ANIMALS; BIOFILMS; CLOXACILLIN; DISEASE MODELS, ANIMAL; FIBRIN; HUMANS; IN VITRO TECHNIQUES; MICE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84953931717     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02803-15     Document Type: Article

References (33)

1. Ahmed S, Darouiche RO. 2015. Anti-biofilm agents in control of devicerelated infections. Adv Exp Med Biol 831:137-146. http://dx.doi.org/10.1007/978-3-319-09782-4_9.
2. Bryers JD. 2008. Medical biofilms. Biotechnol Bioeng 100:1-18. http://dx.doi.org/10.1002/bit.21838.
3. Gristina AG. 1987. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237:1588-1595. http://dx.doi.org/10.1126/science.3629258.
4. Rodrigues LR. 2011. Inhibition of bacterial adhesion on medical devices. Adv Exp Med Biol 715:351-367. http://dx.doi.org/10.1007/978-94-007-0940-9_22.
5. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. 2011. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2:445-459. http://dx.doi.org/10.4161/viru.2.5.17724.
6. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. 2012. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 33:5967-5982. http://dx.doi.org/10.1016/j.biomaterials.2012.05.031.
7. Kiedrowski MR, Horswill AR. 2011. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci 1241:104-121. http://dx.doi.org/10.1111/j.1749-6632.2011.06281.x.
8. Vanassche T, Peetermans M, Van Aelst LN, Peetermans WE, Verhaegen J, Missiakas DM, Schneewind O, Hoylaerts MF, Verhamme P. 2013. The role of staphylothrombin-mediated fibrin deposition in catheterrelated Staphylococcus aureus infections. J Infect Dis 208:92-100. http://dx.doi.org/10.1093/infdis/jit130.
9. Vanassche T, Verhaegen J, Peetermans WE, Van Ryn J, Cheng A, Schneewind O, Hoylaerts MF, Verhamme P. 2011. Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence. J Thromb Haemost 9:2436-2446. http://dx.doi.org/10.1111/j.1538-7836.2011.04529.x.
10. Zapotoczna M, McCarthy H, Rudkin JK, O'Gara JP, O'Neill E. 4 June 2015. An essential role for coagulase in Staphylococcus aureus biofilm development reveals new therapeutic possibilities for device-related infections. J Infect Dis http://dx.doi.org/10.1093/infdis/jiv319.
11. Kwiecinski J, Peetermans M, Liesenborghs L, Na M, Bjornsdottir H, Zhu X, Jacobsson G, Johansson BR, Geoghegan JA, Foster TJ, Josefsson E, Bylund J, Verhamme P, Jin T. 1 July 2015. Staphylokinase control of Staphylococcus aureus biofilm formation and detachment through host plasminogen activation. J Infect Dis http://dx.doi.org/10.1093/infdis/jiv360.
12. Dastgheyb S, Parvizi J, Shapiro IM, Hickok NJ, Otto M. 2015. Effect of biofilms on recalcitrance of staphylococcal joint infection to antibiotic treatment. J Infect Dis 211:641-650. http://dx.doi.org/10.1093/infdis/jiu514.
13. Kwiecinski J, Kahlmeter G, Jin T. 2015. Biofilm formation by Staphylococcus aureus isolates from skin and soft tissue infections. Curr Microbiol 70:698-703. http://dx.doi.org/10.1007/s00284-014-0770-x.
14. Peetermans M, Vanassche T, Liesenborghs L, Claes J, Vande Velde G, Kwiecinksi J, Jin T, De Geest B, Hoylaerts MF, Lijnen RH, Verhamme P. 2014. Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections. BMC Microbiol 14:310. http://dx.doi.org/10.1186/s12866-014-0310-7.
15. Jin T, Bokarewa M, McIntyre L, Tarkowski A, Corey GR, Reller LB, Fowler VG, Jr. 2003. Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strains. J Med Microbiol 52:919-923. http://dx.doi.org/10.1099/jmm.0.05145-0.
16. Kwiecinski J, Jacobsson G, Karlsson M, Zhu X, Wang W, Bremell T, Josefsson E, Jin T. 2013. Staphylokinase promotes the establishment of Staphylococcus aureus skin infections while decreasing disease severity. J Infect Dis 208:990-999. http://dx.doi.org/10.1093/infdis/jit288.
17. Kwiecinski J, Josefsson E, Mitchell J, Higgins J, Magnusson M, Foster T, Jin T, Bokarewa M. 2010. Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection. J Infect Dis 202:1041-1049. http://dx.doi.org/10.1086/656140.
18. Di Poto A, Sbarra MS, Provenza G, Visai L, Speziale P. 2009. The effect of photodynamic treatment combined with antibiotic action or host defence mechanisms on Staphylococcus aureus biofilms. Biomaterials 30: 3158-3166. http://dx.doi.org/10.1016/j.biomaterials.2009.02.038.
19. Jacobsson G, Dashti S, Wahlberg T, Andersson R. 2007. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 39:6-13. http://dx.doi.org/10.1080/00365540600810026.
20. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40:175-179. http://dx.doi.org/10.1016/S0167-7012(00)00122-6.
21. Beyenal H, Donovan C, Lewandowski Z, Harkin G. 2004. Threedimensional biofilm structure quantification. J Microbiol Methods 59: 395-413. http://dx.doi.org/10.1016/j.mimet.2004.08.003.
22. Kwiecinski J, Josefsson E, Jin T. 2011. Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease. Inflamm Res 60:1021-1029. http://dx.doi.org/10.1007/s00011-011-0363-0.
23. Kwiecinski J, Eick S, Wojcik K. 2009. Effects of tea tree (Melaleuca alternifolia) oil on Staphylococcus aureus in biofilms and stationary growth phase. Int J Antimicrob Agents 33:343-347. http://dx.doi.org/10.1016/j.ijantimicag.2008.08.028.
24. Foster TJ, Geoghegan JA, Ganesh VK, Höök M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol 12:49-62.
25. Akiyama H, Ueda M, Kanzaki H, Tada J, Arata J. 1997. Biofilm formation of Staphylococcus aureus strains isolated from impetigo and furuncle: role of fibrinogen and fibrin. J Dermatol Sci 16:2-10. http://dx.doi.org/10.1016/S0923-1811(97)00611-7.
26. Katsuyama M, Ichikawa H, Ogawa S, Ikezawa Z. 2005. A novel method to control the balance of skin microflora. Part 1. Attack on biofilm of Staphylococcus aureus without antibiotics. J Dermatol Sci 38:197-205. http://dx.doi.org/10.1016/j.jdermsci.2005.01.006.
27. Baruah DB, Dash RN, Chaudhari MR, Kadam SS. 2006. Plasminogen activators: a comparison. Vascul Pharmacol 44:1-9. http://dx.doi.org/10.1016/j.vph.2005.09.003.
28. Jin T, Bokarewa M, Zhu Y, Tarkowski A. 2008. Staphylokinase reduces plasmin formation by endogenous plasminogen activators. Eur J Haematol 81:8-17. http://dx.doi.org/10.1111/j.1600-0609.2008.01066.x.
29. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA. 2006. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 21:2247-2255. http://dx.doi.org/10.1093/ndt/gfl170.
30. Dastgheyb S, Hammoud S, Ketonis C, Liu AY, Fitzgerald K, Parvizi J, Purtill J, Ciccotti M, Shapiro IM, Otto M, Hickok NJ. 2015. Staphylococcal persistence due to biofilm formation in synovial fluid containing prophylactic cefazolin. Antimicrob Agents Chemother 59:2122-2128. http://dx.doi.org/10.1128/AAC.04579-14.
31. Guggenberger C, Wolz C, Morrissey JA, Heesemann J. 2012. Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog 8:e1002434. http://dx.doi.org/10.1371/journal.ppat.1002434.
32. Loof T, Goldmann O, Naudin C, Morgelin M, Neumann Y, Pils M, Foster S, Medina E, Herwald H. 2015. Staphylococcus aureus induced clotting of plasma is an immune evasion mechanism to persist within the fibrin network. Microbiology 161(Pt 3):621-627. http://dx.doi.org/10.1099/mic.0.000019.
33. Jin T, Bokarewa M, Tarkowski A. 2005. Urokinase-type plasminogen activator, an endogenous antibiotic. J Infect Dis 192:429-437. http://dx.doi.org/10.1086/431600.